Join to View Full Profile
12200 W 110th StOverland Park, KS 66210
Phone+1 913-574-2650
Fax+1 913-574-2769
Dr. Crane is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Cooper Medical School of Rowan University/Cooper University HospitalFellowship, Hematology and Medical Oncology, 2010 - 2013
Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 2007 - 2010
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2007
Certifications & Licensure
MO State Medical License 2013 - 2027
KS State Medical License 2013 - 2026
NJ State Medical License 2010 - 2013
PA State Medical License 2007 - 2012
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Publications & Presentations
PubMed
- 1 citationsAnalysis of the Radiosensitivity Index in Paired Preneoadjuvant and Postneoadjuvant Therapy Triple-Negative Breast Cancer.Shane R Stecklein, Roberto Salgado, Julia R White, Bruce F Kimler, Rachel Yoder
International Journal of Radiation Oncology, Biology, Physics. 2026-03-01 - 4 citationsRandomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial.Qamar J Khan, Colleen Bohnenkamp, Taylor E Monson, Milind A Phadnis, Lauren Clark
JCO Oncology Advances. 2025-01-01 - 113 citationsClinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.Priyanka Sharma, Shane R Stecklein, Rachel Yoder, Joshua M Staley, Kelsey Schwensen
JAMA Oncology. 2024-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
